

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Letermovir Solid Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 28.09.2024  |
| 4.4     | 14.04.2025     | 59340-00028 | Date of first issue: 16.02.2015 |

### SECTION 1: Identification of the substance/mixture and of the company/undertaking

#### 1.1 Product identifier

Trade name : Letermovir Solid Formulation

#### 1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-  
stance/Mixture : Pharmaceutical

Recommended restrictions  
on use : Not applicable

#### 1.3 Details of the supplier of the safety data sheet

Company : MSD  
Innishannon  
County Cork - Ireland

Telephone : 353 214329300

E-mail address of person  
responsible for the SDS : EHSDATASTEWARD@msd.com

#### 1.4 Emergency telephone number

+1-908-423-6000

### SECTION 2: Hazards identification

#### 2.1 Classification of the substance or mixture

##### Classification (REGULATION (EC) No 1272/2008)

|  |  |
|--|--|
| Reproductive toxicity, Category 2                              | H361d: Suspected of damaging the unborn child.                           |
| Specific target organ toxicity - repeated exposure, Category 2 | H373: May cause damage to organs through prolonged or repeated exposure. |

#### 2.2 Label elements

##### Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms :



Signal word : Warning

|                   |   |       |  |
|-------------------|---|-------|--|
| Hazard statements | : | H361d | Suspected of damaging the unborn child.      |
|                   | : | H373  | May cause damage to organs through prolonged |

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Letermovir Solid Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 28.09.2024  |
| 4.4     | 14.04.2025     | 59340-00028 | Date of first issue: 16.02.2015 |

or repeated exposure.

Precautionary statements : **Prevention:**

P201 Obtain special instructions before use.  
P260 Do not breathe dust.  
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

**Response:**

P308 + P313 IF exposed or concerned: Get medical advice/ attention.

**Storage:**

P405 Store locked up.

### Hazardous components which must be listed on the label:

Letermovir

### 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Dust contact with the eyes can lead to mechanical irritation.  
Contact with dust can cause mechanical irritation or drying of the skin.  
May form explosive dust-air mixture during processing, handling or other means.

## SECTION 3: Composition/information on ingredients

### 3.2 Mixtures

#### Components

| Chemical name | CAS-No.<br>EC-No.<br>Index-No.<br>Registration number | Classification  | Concentration<br>(% w/w) |
|---------------|---|---|--------------------------|
| Letermovir    | 917389-32-3   | Repr. 2; H361d<br>STOT RE 2; H373<br>(Liver, spleen, Blood) | >= 30 - < 50             |

For explanation of abbreviations see section 16.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Letermovir Solid Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 28.09.2024  |
| 4.4     | 14.04.2025     | 59340-00028 | Date of first issue: 16.02.2015 |

### SECTION 4: First aid measures

#### 4.1 Description of first aid measures

- |                            |   |   |
|----------------------------|---|---|
| General advice             | : | In the case of accident or if you feel unwell, seek medical advice immediately.<br>When symptoms persist or in all cases of doubt seek medical advice.  |
| Protection of first-aiders | : | First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).   |
| If inhaled                 | : | If inhaled, remove to fresh air.<br>Get medical attention.  |
| In case of skin contact    | : | In case of contact, immediately flush skin with soap and plenty of water.<br>Remove contaminated clothing and shoes.<br>Get medical attention.<br>Wash clothing before reuse.<br>Thoroughly clean shoes before reuse. |
| In case of eye contact     | : | If in eyes, rinse well with water.<br>Get medical attention if irritation develops and persists.  |
| If swallowed               | : | If swallowed, DO NOT induce vomiting.<br>Get medical attention.<br>Rinse mouth thoroughly with water.   |

#### 4.2 Most important symptoms and effects, both acute and delayed

- |       |   |  |
|-------|---|--|
| Risks | : | Contact with dust can cause mechanical irritation or drying of the skin.<br>Dust contact with the eyes can lead to mechanical irritation.<br><br>Suspected of damaging the unborn child.<br>May cause damage to organs through prolonged or repeated exposure. |
|-------|---|--|

#### 4.3 Indication of any immediate medical attention and special treatment needed

- |           |   |   |
|-----------|---|---|
| Treatment | : | Treat symptomatically and supportively. |
|-----------|---|---|

### SECTION 5: Firefighting measures

#### 5.1 Extinguishing media

- |                              |   |  |
|------------------------------|---|--|
| Suitable extinguishing media | : | Water spray<br>Alcohol-resistant foam<br>Carbon dioxide (CO <sub>2</sub> )<br>Dry chemical |
|------------------------------|---|--|

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Letermovir Solid Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 28.09.2024  |
| 4.4     | 14.04.2025     | 59340-00028 | Date of first issue: 16.02.2015 |

Unsuitable extinguishing media : None known.

### 5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.  
Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides  
Metal oxides  
Nitrogen oxides (NO<sub>x</sub>)

### 5.3 Advice for firefighters

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.

## SECTION 6: Accidental release measures

### 6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

### 6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.

### 6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.  
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).  
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Letermovir Solid Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 28.09.2024  |
| 4.4     | 14.04.2025     | 59340-00028 | Date of first issue: 16.02.2015 |

mine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding  
certain local or national requirements.

### 6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

## SECTION 7: Handling and storage

### 7.1 Precautions for safe handling

- |                         |   |  |
|-------------------------|---|--|
| Technical measures      | : | Static electricity may accumulate and ignite suspended dust causing an explosion.<br>Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.   |
| Local/Total ventilation | : | Use only with adequate ventilation.  |
| Advice on safe handling | : | Do not breathe dust.<br>Do not swallow.<br>Avoid contact with eyes.<br>Avoid prolonged or repeated contact with skin.<br>Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment<br>Minimize dust generation and accumulation.<br>Keep container closed when not in use.<br>Keep away from heat and sources of ignition.<br>Take precautionary measures against static discharges.<br>Take care to prevent spills, waste and minimize release to the environment. |
| Hygiene measures        | : | If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.<br>The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.   |

### 7.2 Conditions for safe storage, including any incompatibilities

- |   |   |  |
|---|---|--|
| Requirements for storage areas and containers | : | Keep in properly labelled containers. Store locked up. Store in accordance with the particular national regulations. |
| Advice on common storage                      | : | Do not store with the following product types:<br>Strong oxidizing agents  |

### 7.3 Specific end use(s)

- |                 |   |                   |
|-----------------|---|-------------------|
| Specific use(s) | : | No data available |
|-----------------|---|-------------------|

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Letermovir Solid Formulation

Version 4.4      Revision Date: 14.04.2025      SDS Number: 59340-00028      Date of last issue: 28.09.2024  
Date of first issue: 16.02.2015

### SECTION 8: Exposure controls/personal protection

#### 8.1 Control parameters

##### Occupational Exposure Limits

dusts non-specific

4 mg/m<sup>3</sup>

Value type (Form of exposure): OELV - 8 hrs (TWA) (Respirable dust)

Basis: IE OEL

10 mg/m<sup>3</sup>

Value type (Form of exposure): OELV - 8 hrs (TWA) (inhalable dust)

Basis: IE OEL

| Components         | CAS-No.     | Value type (Form of exposure)        | Control parameters             | Basis    |
|--------------------|-------------|--------------------------------------|--------------------------------|----------|
| Cellulose          | 9004-34-6   | OELV - 8 hrs (TWA)                   | 10 mg/m <sup>3</sup>           | IE OEL   |
| Letermovir         | 917389-32-3 | TWA                                  | 0.4 mg/m <sup>3</sup> (OEB 2)  | Internal |
| Silicon dioxide    | 7631-86-9   | OELV - 8 hrs (TWA) (Respirable dust) | 2.4 mg/m <sup>3</sup> (Silica) | IE OEL   |
|                    |             | OELV - 8 hrs (TWA) (inhalable dust)  | 6 mg/m <sup>3</sup> (Silica)   | IE OEL   |
| Magnesium stearate | 557-04-0    | OELV - 8 hrs (TWA)                   | 10 mg/m <sup>3</sup>           | IE OEL   |

##### Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006

| Substance name  | End Use | Exposure routes | Potential health effects   | Value               |
|-----------------|---------|-----------------|----------------------------|---------------------|
| Silicon dioxide | Workers | Inhalation      | Long-term systemic effects | 4 mg/m <sup>3</sup> |

#### 8.2 Exposure controls

##### Engineering measures

Use feasible engineering controls to minimize exposure to compound.

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

##### Personal protective equipment

Eye/face protection : Wear safety glasses with side shields or goggles.  
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.  
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Hand protection

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Letermovir Solid Formulation

|                |                              |                            |   |
|----------------|------------------------------|----------------------------|---|
| Version<br>4.4 | Revision Date:<br>14.04.2025 | SDS Number:<br>59340-00028 | Date of last issue: 28.09.2024<br>Date of first issue: 16.02.2015 |
|----------------|------------------------------|----------------------------|---|

|                          |   |
|--------------------------|---|
| Material                 | : Chemical-resistant gloves   |
| Skin and body protection | : Work uniform or laboratory coat.  |
| Respiratory protection   | : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.<br>Equipment should conform to I.S. EN 143 |
| Filter type              | : Particulates type (P)   |

### SECTION 9: Physical and chemical properties

#### 9.1 Information on basic physical and chemical properties

|  |   |
|--|---|
| Physical state                                   | : powder  |
| Colour   | : No data available   |
| Odour  | : No data available   |
| Odour Threshold                                  | : No data available   |
| Melting point/freezing point                     | : No data available   |
| Initial boiling point and boiling range          | : No data available   |
| Flammability (solid, gas)                        | : May form explosive dust-air mixture during processing, handling or other means. |
| Flammability (liquids)                           | : No data available   |
| Upper explosion limit / Upper flammability limit | : No data available   |
| Lower explosion limit / Lower flammability limit | : No data available   |
| Flash point                                      | : Not applicable  |
| Auto-ignition temperature                        | : No data available   |
| Decomposition temperature                        | : No data available   |
| pH   | : No data available   |
| Viscosity  |   |
| Viscosity, kinematic                             | : Not applicable  |
| Solubility(ies)                                  |   |
| Water solubility                                 | : No data available   |

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Letermovir Solid Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 28.09.2024  |
| 4.4     | 14.04.2025     | 59340-00028 | Date of first issue: 16.02.2015 |

|   |   |                   |
|---|---|-------------------|
| Partition coefficient: n-octanol/water    | : | Not applicable    |
| Vapour pressure                           | : | Not applicable    |
| Relative density                          | : | No data available |
| Density                                   | : | No data available |
| Relative vapour density                   | : | Not applicable    |
| Particle characteristics<br>Particle size | : | No data available |

### 9.2 Other information

|                      |   |  |
|----------------------|---|--|
| Explosives           | : | Not explosive  |
| Oxidizing properties | : | The substance or mixture is not classified as oxidizing. |
| Evaporation rate     | : | Not applicable   |

## SECTION 10: Stability and reactivity

### 10.1 Reactivity

Not classified as a reactivity hazard.

### 10.2 Chemical stability

Stable under normal conditions.

### 10.3 Possibility of hazardous reactions

|                     |   |  |
|---------------------|---|--|
| Hazardous reactions | : | May form explosive dust-air mixture during processing, handling or other means.<br>Can react with strong oxidizing agents. |
|---------------------|---|--|

### 10.4 Conditions to avoid

|                     |   |   |
|---------------------|---|---|
| Conditions to avoid | : | Heat, flames and sparks.<br>Avoid dust formation. |
|---------------------|---|---|

### 10.5 Incompatible materials

|                    |   |                  |
|--------------------|---|------------------|
| Materials to avoid | : | Oxidizing agents |
|--------------------|---|------------------|

### 10.6 Hazardous decomposition products

No hazardous decomposition products are known.

## SECTION 11: Toxicological information

### 11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of : Inhalation



# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Letermovir Solid Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 28.09.2024  |
| 4.4     | 14.04.2025     | 59340-00028 | Date of first issue: 16.02.2015 |

---

|          |              |
|----------|--------------|
| exposure | Skin contact |
|          | Ingestion    |
|          | Eye contact  |

### Acute toxicity

Not classified based on available information.

### Components:

#### Letermovir:

|                     |                             |
|---------------------|-----------------------------|
| Acute oral toxicity | : LD50 (Rat): > 2,000 mg/kg |
|                     | LD50 (Mouse): > 2,000 mg/kg |

### Skin corrosion/irritation

Not classified based on available information.

### Components:

#### Letermovir:

|         |                     |
|---------|---------------------|
| Remarks | : No data available |
|---------|---------------------|

### Serious eye damage/eye irritation

Not classified based on available information.

### Components:

#### Letermovir:

|         |                     |
|---------|---------------------|
| Remarks | : No data available |
|---------|---------------------|

### Respiratory or skin sensitisation

#### Skin sensitisation

Not classified based on available information.

#### Respiratory sensitisation

Not classified based on available information.

### Components:

#### Letermovir:

|         |                     |
|---------|---------------------|
| Remarks | : No data available |
|---------|---------------------|

### Germ cell mutagenicity

Not classified based on available information.

### Components:

#### Letermovir:

|                       |  |
|-----------------------|--|
| Genotoxicity in vitro | : Test Type: Bacterial reverse mutation assay (AMES) |
|                       | Result: negative                                     |
|                       | Test Type: Chromosome aberration test in vitro       |

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Letermovir Solid Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 28.09.2024  |
| 4.4     | 14.04.2025     | 59340-00028 | Date of first issue: 16.02.2015 |

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)  
Species: Mouse  
Application Route: Intraperitoneal injection  
Result: negative

Germ cell mutagenicity- Assessment : Weight of evidence does not support classification as a germ cell mutagen.

### Carcinogenicity

Not classified based on available information.

### Reproductive toxicity

Suspected of damaging the unborn child.

### Components:

#### Letermovir:

Effects on fertility : Test Type: Fertility/early embryonic development  
Species: Rat, female  
Application Route: Oral  
Fertility: NOAEL: 240 mg/kg body weight  
Result: No effects on fertility

Test Type: Fertility/early embryonic development  
Species: Rat, male  
Application Route: Oral  
Fertility: LOAEL: 180 mg/kg body weight  
Result: No effects on fertility  
Remarks: The significance of these findings for humans is not certain.

Test Type: Fertility/early embryonic development  
Species: Monkey, male  
Application Route: Oral  
Fertility: NOAEL: 240 mg/kg body weight  
Result: No effects on fertility

Effects on foetal development : Test Type: Embryo-foetal development  
Species: Rat  
Developmental Toxicity: LOAEL: 250 mg/kg body weight  
Result: Embryo-foetal toxicity  
Remarks: Maternal toxicity observed.

Test Type: Embryo-foetal development  
Species: Rabbit  
Developmental Toxicity: LOAEL: 225 mg/kg body weight  
Result: Embryo-foetal toxicity, Malformations were observed., Abortion  
Remarks: Maternal toxicity observed.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Letermovir Solid Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 28.09.2024  |
| 4.4     | 14.04.2025     | 59340-00028 | Date of first issue: 16.02.2015 |

Reproductive toxicity - Assessment : Some evidence of adverse effects on development, based on animal experiments.

### STOT - single exposure

Not classified based on available information.

### STOT - repeated exposure

May cause damage to organs through prolonged or repeated exposure.

### Components:

#### Letermovir:

|                 |  |
|-----------------|--|
| Exposure routes | : Ingestion  |
| Target Organs   | : Liver, spleen, Blood   |
| Assessment      | : May cause damage to organs through prolonged or repeated exposure. |

### Repeated dose toxicity

### Components:

#### Letermovir:

|                   |                 |
|-------------------|-----------------|
| Species           | : Mouse         |
| NOAEL             | : 40 mg/kg      |
| LOAEL             | : 100 mg/kg     |
| Application Route | : Oral          |
| Exposure time     | : 13 Weeks      |
| Target Organs     | : Liver, spleen |

|                   |  |
|-------------------|--|
| Species           | : Rat  |
| NOAEL             | : 150 mg/kg                                    |
| Application Route | : Oral   |
| Exposure time     | : 26 Weeks                                     |
| Remarks           | : No significant adverse effects were reported |

|                   |                   |
|-------------------|-------------------|
| Species           | : Monkey          |
| NOAEL             | : 100 mg/kg       |
| LOAEL             | : 200 - 250 mg/kg |
| Application Route | : Oral            |
| Exposure time     | : 39 Weeks        |
| Target Organs     | : Kidney          |

|               |   |
|---------------|---|
| Species       | : Rat   |
| NOAEL         | : 60 mg/kg                                    |
| LOAEL         | : 180 mg/kg                                   |
| Exposure time | : 13 Weeks                                    |
| Target Organs | : Testis, Blood, Liver, spleen, Immune system |

|                   |             |
|-------------------|-------------|
| Species           | : Monkey    |
| NOAEL             | : 30 mg/kg  |
| LOAEL             | : 100 mg/kg |
| Application Route | : Oral      |
| Exposure time     | : 4 Weeks   |

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Letermovir Solid Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 28.09.2024  |
| 4.4     | 14.04.2025     | 59340-00028 | Date of first issue: 16.02.2015 |

Target Organs : Blood

### Aspiration toxicity

Not classified based on available information.

### 11.2 Information on other hazards

#### Endocrine disrupting properties

Not classified based on available information.

#### Product:

Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

#### Experience with human exposure

#### Components:

##### Letermovir:

Ingestion : Symptoms: Diarrhoea, Nausea, Vomiting, Headache, Dizziness, Fatigue, Back pain, Oedema, Rash, muscle pain

## SECTION 12: Ecological information

### 12.1 Toxicity

#### Components:

##### Letermovir:

Toxicity to fish : LC50 (Menidia beryllina (Silverside)): > 100 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 203

Toxicity to daphnia and other : EC50 (Americamysis): 16 mg/l  
aquatic invertebrates Exposure time: 96 h

EC50 (Daphnia magna (Water flea)): > 100 mg/l  
Exposure time: 48 h  
Method: OECD Test Guideline 202

Toxicity to algae/aquatic : EC50 (Pseudokirchneriella subcapitata (green algae)): > 8.8  
plants mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201  
Remarks: No toxicity at the limit of solubility

NOEC (Pseudokirchneriella subcapitata (green algae)): 8.8  
mg/l  
Exposure time: 72 h

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Letermovir Solid Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 28.09.2024  |
| 4.4     | 14.04.2025     | 59340-00028 | Date of first issue: 16.02.2015 |

Method: OECD Test Guideline 201  
Remarks: No toxicity at the limit of solubility

Toxicity to microorganisms : EC50 : > 972 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209

NOEC : 29.6 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209

Toxicity to fish (Chronic toxicity) : NOEC: 1 mg/l  
Exposure time: 32 d  
Species: Pimephales promelas (fathead minnow)  
Method: OECD Test Guideline 210  
Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC: 1.2 mg/l  
Exposure time: 21 d  
Species: Daphnia magna (Water flea)  
Method: OECD Test Guideline 211

### 12.2 Persistence and degradability

#### Components:

##### **Letermovir:**

Biodegradability : Result: rapidly degradable  
Biodegradation: 50 %  
Exposure time: 6.7 d

### 12.3 Bioaccumulative potential

#### Components:

##### **Letermovir:**

Partition coefficient: n-octanol/water : log Pow: 2.29

### 12.4 Mobility in soil

#### Components:

##### **Letermovir:**

Distribution among environmental compartments : log Koc: 3.46

### 12.5 Results of PBT and vPvB assessment

#### Product:

Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Letermovir Solid Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 28.09.2024  |
| 4.4     | 14.04.2025     | 59340-00028 | Date of first issue: 16.02.2015 |

very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

### 12.6 Endocrine disrupting properties

#### **Product:**

Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

### 12.7 Other adverse effects

No data available

## SECTION 13: Disposal considerations

### 13.1 Waste treatment methods

|                        |  |
|------------------------|--|
| Product                | : Dispose of in accordance with local regulations.<br>According to the European Waste Catalogue, Waste Codes are not product specific, but application specific.<br>Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.<br>Do not dispose of waste into sewer. |
| Contaminated packaging | : Empty containers should be taken to an approved waste handling site for recycling or disposal.<br>If not otherwise specified: Dispose of as unused product.  |

## SECTION 14: Transport information

### 14.1 UN number or ID number

|      |                                     |
|------|-------------------------------------|
| ADN  | : Not regulated as a dangerous good |
| ADR  | : Not regulated as a dangerous good |
| RID  | : Not regulated as a dangerous good |
| IMDG | : Not regulated as a dangerous good |
| IATA | : Not regulated as a dangerous good |

### 14.2 UN proper shipping name

|      |                                     |
|------|-------------------------------------|
| ADN  | : Not regulated as a dangerous good |
| ADR  | : Not regulated as a dangerous good |
| RID  | : Not regulated as a dangerous good |
| IMDG | : Not regulated as a dangerous good |
| IATA | : Not regulated as a dangerous good |

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Letermovir Solid Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 28.09.2024  |
| 4.4     | 14.04.2025     | 59340-00028 | Date of first issue: 16.02.2015 |

### 14.3 Transport hazard class(es)

|      |                                     |
|------|-------------------------------------|
| ADN  | : Not regulated as a dangerous good |
| ADR  | : Not regulated as a dangerous good |
| RID  | : Not regulated as a dangerous good |
| IMDG | : Not regulated as a dangerous good |
| IATA | : Not regulated as a dangerous good |

### 14.4 Packing group

|                  |                                     |
|------------------|-------------------------------------|
| ADN              | : Not regulated as a dangerous good |
| ADR              | : Not regulated as a dangerous good |
| RID              | : Not regulated as a dangerous good |
| IMDG             | : Not regulated as a dangerous good |
| IATA (Cargo)     | : Not regulated as a dangerous good |
| IATA (Passenger) | : Not regulated as a dangerous good |

### 14.5 Environmental hazards

Not regulated as a dangerous good

### 14.6 Special precautions for user

Not applicable

### 14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.

## SECTION 15: Regulatory information

### 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

|   |                  |
|---|------------------|
| REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII)              | : Not applicable |
| REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59).   | : Not applicable |
| Regulation (EU) No 2024/590 on substances that deplete the ozone layer  | : Not applicable |
| Regulation (EU) 2019/1021 on persistent organic pollutants (recast)   | : Not applicable |
| Regulation (EU) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals                          | : Not applicable |
| REACH - List of substances subject to authorisation (Annex XIV)   | : Not applicable |
| Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances. |                  |
| Not applicable  |                  |

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Letermovir Solid Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 28.09.2024  |
| 4.4     | 14.04.2025     | 59340-00028 | Date of first issue: 16.02.2015 |

### Other regulations:

Take note of Directive 92/85/EEC regarding maternity protection or stricter national regulations, where applicable.

Take note of Directive 94/33/EC on the protection of young people at work or stricter national regulations, where applicable.

### The components of this product are reported in the following inventories:

|       |                  |
|-------|------------------|
| AICS  | : not determined |
| DSL   | : not determined |
| IECSC | : not determined |

### 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

## SECTION 16: Other information

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

### Full text of H-Statements

|       |   |
|-------|---|
| H361d | : Suspected of damaging the unborn child.   |
| H373  | : May cause damage to organs through prolonged or repeated exposure if swallowed. |

### Full text of other abbreviations

|                             |   |
|-----------------------------|---|
| Repr.                       | : Reproductive toxicity   |
| STOT RE                     | : Specific target organ toxicity - repeated exposure  |
| IE OEL                      | : Ireland. List of Chemical Agents and Carcinogens with Occupational Exposure Limit Values - Code of Practice, Schedule 1 and 2 |
| IE OEL / OELV - 8 hrs (TWA) | : Occupational exposure limit value (8-hour reference period)   |

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL



# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Letermovir Solid Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 28.09.2024  |
| 4.4     | 14.04.2025     | 59340-00028 | Date of first issue: 16.02.2015 |

- Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

### Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

### Classification of the mixture:

|           |       |
|-----------|-------|
| Repr. 2   | H361d |
| STOT RE 2 | H373  |

### Classification procedure:

|                    |
|--------------------|
| Calculation method |
| Calculation method |

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IE / EN